White House Petition:
https://petitions.whitehouse.gov/petition/approve-leronlimab-treatment-covid-illness-immediately-proven-safe
Approve leronlimab for the treatment of COVID illness immediately. Proven safe.
Created by A.L. on July 12, 2020

In RCT trials currently, reporting shortly. Calms/prevents the cytokine storm. Reduces the viral load. Restores the immune system. Saves lives. For mild and moderate cases, outpatient treatment possible, with no IV or hospital bed required. No side effects. Google it. Twitter it. Minutes 7 - 29 of the attached TEDx talk by Dr. Patterson explains it all. This is the world's best chance to address the problem. Push BP to the side and have the FDA approve it post haste.

https://vimeo.com/429981545

I suspect we'll get a short attack (Bear Raid) before the Covid results are announced!

Mild to moderate results will be published immediately when the FDA reviews the results and wants / needs to inform the public.

I expect we'll see the results between July 17th through July 24th.

Fortunately, PDUFA will be earlier on July 10th and hopefully without delay. So the shortis still have exactly 3 trading days to start an attack and screw stop-loss investors and nervous nellies.

I guess it will be a shorttime and medium to heavy attack. Either you take the stop loss out and take a risk if PDUFA Info doesn't get quick approval and thus a course correction takes place (which I don't think).

Or if a phase 3 for MtM is required for Covid results due to insufficient informative value of 75 probands.

Some possible chart analysis scenarios for the PPS ...


Almost all indicators ??have consolidated "for a short time", but since there is not much time when positive results are aroundcome, I see a short dip as given and therefore possible.

Since there was no news today, it will be exciting whether the gap will be closed at $ 6.08 or it goes down to the second barrier, clearly it can only happen tomorrow or on Thursday - or might not at all, because there are too many interested parties on the buyer side.

I take risks and go without Stop-Loss!

IMHO & GLTA & SLSS (Stay Long Stay Strong) & CU@10

CytoDyn $CYDY mit Blockbuster Potential WKN: A0YHA5 | wallstreet-online.de - Vollständige Diskussion unter:
https://www.wallstreet-online.de/diskussion/1301376-neustebeitraege/cytodyn-cydy-blockbuster-potential-wkn-a0yha5

Today or this week before the 4th of July (Independence Day) we will see Alexander Hamilton (Treasury Secretary under G. Washington), I am drawing in advance - who is drawing with me please like the post!

Cytodyn has an amazing power.
It is just at the beginning & I think it's just starting to unfold its true potential.
At the Wallstreet Online Board in Germany i wrote, that I value Covid-19 with at least $10 bn Market Cap, but with the 2nd wave of Covid around the Globe it could easily be $15 bn, which gives Cytodyn a PPS fully diluted with 700 mn shares a staggering PPS of

=======> $ 21,40 only for Covid-19,

excluding all other implications that will take place sooner or later!
Cytodyn will be the GIANT in the Pharma area, which was never seen before!
IMHO & GLTA
Have a nice evening across the pond or wherever you are....
I will have a peaceful night & sleep like a Baby after this excellent day!
N8 All till tomorrow and cheers from Germany

Sunny

Germany quotes (Berlin/Stuttgart/Munich):

$7,58 = 6,50 Euro!

https://wertpapiere.ing.de/Investieren/Aktie/Boersen/US23283M1018

https://www.boerse-stuttgart.de/de-de/produkte/aktien/stuttgart/a0yha5-cytodyn-inc------dl--01/times-and-sales

LifeLongLearner, something went wrong with the question marks (typos), sorry for that and yes ilve in Germany!

Cheers from Stuttgart- Germany!

I conclude that this will might due uncertainty who else is already infected and might show no symptoms or even doesn‘t get a positive test due to several days of incubation time!

This will cause a hell of panic and a Leron shot might be cheaper than loosing several soldiers without being at the war front!

One will might happen that Shorts will see their Armageddon!

IMHO & GLTA

Cheers ?? from Germany ????

LifeLongLearner thank you and yes all is good in „Good Old Germany“ ????

Hope for another excellent week for CYDY!

We might see 10 bucks when PRs fall into place and announce a major milestone or partner!

IMHO & GLTA

Greetings from Germany ????

CYTODYN KEY CATALYSTS
Covid-19 Situational Overview
https://lookaside.fbsbx.com/file/Cytodyn%20Catalysts%20-%20Covid.pdf?token=AWxTagTfUk4v7CUQvsFt8jNZhgUA7RVxMtgYvbj1HrC92yz3ZvqOFnyFpdBohArv8MZG6Gpq4rw28OEgSgFNerYz3E9SP5YkSHEeODXNuDr1offj4Fg-w25tXsz6lDUTHLMhOEXFT9Q3PAGnTwSzCQ8dxb3w3RUTtY0xQtSSlBr1XQTp7YKUDGmH0HAiTcONkqXIJJTNh5I9g-kFCjSrvhz2

New York Times:
How the Coronavirus Short-Circuits the Immune System
In a disturbing parallel to H.I.V., the coronavirus can cause a depletion of important immune cells, recent studies found.
By Gina Kolata not Pina Calada
June 26, 2020
https://www.nytimes.com/2020/06/26/health/coronavirus-immune-system.html

Sunday musing in medicinal news from India (2):
Tackling SARS-CoV-2: proposed targets and repurposed drugs
https://www.future-science.com/doi/pdfplus/10.4155/fmc-2020-0147

Sunday musing in medicinal news from Italy (1):
SARS-CoV-2 infection in kidney transplant recipients:
Experience of the Italian Marche region
https://onlinelibrary.wiley.com/doi/epdf/10.1111/tid.13377

Leronlimab: CytoDyn Inc (OTCMKTS:CYDY) The Bull Has Awoken

https://microcapdaily.com/leronlimab-cytodyn-inc-otcmktscydy-the-bull-has-awoken/126120/

CytoDyn Inc Stock Rockets 90% in a Week on technical Breakout

https://pennystocks.news/cydy-cytodyn-inc-stock-rockets-90-in-a-week-on-technical-breakout-cydy/

For some with COVID-19, symptoms can linger for weeks, even months
CORONAVIRUS June 19, 2020
By Helena Oliviero, The Atlanta Journal-Constitution

Excerpt:
Reisman knew about a post-COVID trial for survivors of mild to moderate COVID-19 symptoms. Riley enrolled in the clinical trial for leronlimab, a drug that was originally developed to treat HIV, but is showing promise in the coronavirus fight.

He had four injections in his stomach over two weeks.Riley said he immediately felt better. He returned to a faster pace, his blood pressure returned to normal and the other symptoms – the anxiety, the insomnia — faded.It’s possible he was given a placebo or perhaps it was time that helped him heal, but Riley is confident that it was the leronlimab.

A lab technician works during research on coronavirus, COVID-19, at Johnson & Johnson subsidiary Janssen Pharmaceutical in Beerse, Belgium, Wednesday, June 17, 2020. Janssen Pharmaceutical hopes to begin clinical trials on a potential vaccine for COVID-19 in the middle of the summer.

Doctor who was also COVID-19 patient Dr. Chris Recknor, a Gainesville internist who runs one of the six sites for the leronlimab clinical trial, is also a COVID-19 survivor.He first got sick in April, starting with an intense headache. Then, he started bumping into things and saw floaters in his eyes. Those aren’t the most common coronavirus symptoms, but he knew something wasn’t right and decided to get tested to, if nothing else, rule out the infectious virus. The test was positive.His conditioned worsened to the point where he thought he might have a heart attack.

He ended up in ER at Northeast Georgia Medical Center three times and was twice admitted for overnight stays.“I felt like my heart was pumping so hard, it felt like it was coming out of my ears,” he said.His physician at the hospital obtained “compassionate use” permission from the Food and Drug Administration to prescribe leronlimab.

https://www.ajc.com/lifestyles/health/for-some-with-covid-symptoms-can-linger-for-weeks-even-months/0rzLkWZWeXh0D2y3ezEqcN/

Medical Research of Leronlimab:

European Heart Journal (Oxford Academic):
https://academic.oup.com/eurheartj/article/41/22/2092/5854666

Phillipines:
https://pps.org.ph/wp-content/uploads/2020/06/A-Review-of-Immunomodulators-as-Therapeutic-Interventions-for-Moderate-to-Severe-Covid-19-Infections.pdf

CCR5 Board (Mentions Dr. Mike Hansen & Eric Feigl-Ding):
http://www.911forum.org.uk/board/viewtopic.php?p=180628

Please show me one company in the world that targets this amount of (deadly) diseases with one drug!

https://www.cytodyn.com/pipeline

NBC News regards Cancer and Covid

Oh and Leronlimab treats cancer too. Currently undergoing trials for breast cancer and 22 solid tumor cancers with great initial results. @CytoDyn pic.twitter.com/xWY3gfbxvw

— gmanyup (@lakermemes818) May 29, 2020

Can Leronlimab (PRO 140) be used to treat COVID-19 (coronavirus)?
Medically reviewed by Melisa Puckey, BPharm Last updated on Mar 29, 2020.

https://www.drugs.com/medical-answers/leronlimab-pro-140-treat-covid-19-coronavirus-3535182/

German News: Warning of quick approval of Remdesivir
As of May 28, 2020 at 6:00 a.m.
https://translate.google.de/translate?sl=de&tl=en&u=https%3A%2F%2Fwww.tagesschau.de%2Finvestigativ%2Fndr%2Fremdesivir-107.html

100,000 Dead, 40 Million Unemployed: America Hits Grim Pandemic Milestones......while a trial from biotech firm CytoDyn is pairing it with an antiviral called leronlimab.
https://www.doctorslounge.com/index.php/news/hd/96103

Bloomberg Report Excerpt: CytoDyn Inc. (OTCQB: CYDY) announced last week it is offering comprehensive
cytokine profiling (including RANTES levels) through its diagnostic partner
company, IncellDx, to help physicians understand the pathogenesis of Childhood
Inflammatory Disease Related to COVID-19. These laboratory tests are
exploratory in nature and not intended for clinical decision making.

Recent reports in parts of the U.S. and Europe suggest a rare and potentially
fatal inflammatory disease linked to the novel coronavirus is afflicting a
small number of children. The condition resembles a rare childhood illness
called Kawasaki disease, which has similar signs and symptoms and can lead to
enlargement of blood vessels that in severe forms may cause heart
damage. Nader Pourhassan, Ph.D., President and Chief Executive Officer of
CytoDyn added, "We hope our comprehensive cytokine testing will help
physicians gain a better understanding of the disease process and, in turn,
explore the prospect for leronlimab to potentially provide a therapeutic
benefit to children suffering from inflammatory illness related to COVID-19."
https://www.bloomberg.com/press-releases/2020-05-26/personal-protective-equipment-eases-fears-during-period-of-global-unrest

India calling Leronlimab a potential treating for Covid-19!

https://www.medindia.net/news/leronlimab-holds-potential-in-treating-covid-19-195157-1.htm

CytoDyn (OTCMKTS:CYDY) Investor Update Unveils Coming Uplisting and Potential Interim Readout Followed by a Massive Development Pipeline Plan

https://biopharmajournal.com/2020/05/27/cytodyn-otcmktscydy-investor-update-unveils-coming-uplisting-and-potential-interim-readout-followed-by-a-massive-development-pipeline-plan/

Coronavirus Cases Ticking Upwards in Nearly a Dozen U.S. States

Excerpt: For example, one federally funded clinical trial is combining remdesivir with a potent anti-inflammatory drug called baricitinib, while a trial from biotech firm CytoDyn is pairing it with an antiviral called leronlimab.
https://consumer.healthday.com/infectious-disease-information-21/coronavirus-1008/coronavirus-cases-ticking-upwards-in-nearly-a-dozen-u-s-states-758013.html

From Middle East: Dr Atef about Leronlimab official website Educational For doctors , Medical Students , Nurses ,Patient etc

http://dratef.net/leronlimab-rantes-covid-19-coronavirus-discussion-with-dr-bruce-patterson-of-incelldx-live-qa/

Leronlimab in Russia:

https://gmpnews.ru/2020/05/leronlimab-pokazyvaet-vysokuyu-effektivnost-pri-lechenii-covid-19/

Leronlimab is highly effective in treating COVID-19
05/26/2020632

The drug leronlimab (leronlimab) from the American company CytoDyn, specializing in the development of therapy with monoclonal antibodies, is a promising candidate for the treatment of COVID-19 . Experts at GlobalData , a research firm, forecast that its peak sales could reach $ 747 million in 2026, which puts it in second place after remdesivir from Gilead Sciences.

Leronlimab is a humanized monoclonal antibody IgG4 that blocks the CCR5 cell receptor, which plays a crucial role in HIV infection, tumor growth (metastasis) and other diseases, including non-alcoholic steatohepatitis. The drug was originally developed for the treatment of human immunodeficiency virus (HIV). Leronlimab has FDA Fast Track status as part of combination antiretroviral therapy for HIV patients and metastatic triple negative breast cancer therapy.

According to GlobalData, leronlimab behind in the evaluation of remdesivira because the drug from Gilead already has permission to FDA for an emergency use in emergencies in the US, Japan, the drug is approved for COVID-19 treatment under the tradename Veklury® and that is not important enough, remdesivir is being developed by one of the ten leading biotechnological companies in the USA - Gilead, which is the market leader in antiviral drugs.

Situation commented Joanna Swanson (Johanna Swanson), a grocery manager GlobalData:

“Leronlimab is currently in phase III clinical trials, making it one of the leading drugs in the research phase with respect to COVID-19. Leronlimab is being studied in two clinical trials. One has 75 participants, the other has 390.

A small observational study recently showed that Leronlimab can reduce viral load and help restore the immune system of patients with COVID-19. According to IncellDx, in critically ill patients there was a sharp restoration of immunity and extubation within seven days after treatment.

Although these results are promising, they are based on a small sample of only ten patients. To confirm these data, larger placebo-controlled clinical trials are needed.

Leronlimab is currently undergoing two clinical trials based on the drug’s ability to mitigate the cytokine storm. ”

Recall that on May 18, CytoDyn announced that it intends to submit to the FDA a phase III test report to test the design of the study, which consists in comparing the efficacy of leronlimab and remdesivir , as well as in combination with remdesivir .

CytoDyn has already received a guarantee from the manufacturer that this year more than 1 million bottles will be available, with a subsequent increase in production to 2-3 million bottles of the drug.

Korea Biomedical Review: [News Focus] Remdesivir alone not enough to kill Covid-19

http://m.koreabiomed.com/news/articleView.html?idxno=8362

Excerpt:
Lilly’s rheumatoid arthritis drug baricitinib (brand name: Olumiant) and CytoDyn’s HIV drug leronlimab are being cited as the most likely medications to maximize remdesivir’s therapeutic effect on Covid-19.

U.S. researchers recently registered a clinical trial on a combo therapy of remdesivir and baricitinib, and CytoDyn is also preparing a trial on leronlimab plus remdesivir in the U.S.

Baricitinib drew attention after the release of genomic information of the Covid-19 virus in January revealed that the virus utilizes “ACE2,” a cell-surface protein when entering the human body.

A research team led by Professor Justin Stebbing at Imperial College searched for numb-associated kinase (NAK)-targeting drugs involved in ACE2’s endocytosis. It found 47 licensed medications out of the 378 candidates. Among the 47, the team picked baricitinib as the best candidate for Covid-19 treatment.

The study was published in The Lancet in early February.

The researchers said that baricitinib would be effective on seriously ill Covid-19 patients’ increased cytokine because the agent blocks the viral entry and inhibits JAK-STAT signaling. The team also mentioned baricitinib’s potential for use in a combo therapy because it has little drug interaction with antiviral agents that are used as an alternative to Covid-19 treatment.

Richard Novak, head of infectious disease research with the University of Illinois at Chicago (UIC), is leading the U.S. trial on the combo of remdesivir and baricitinib. Novak expected that baricitinib’s anti-inflammatory effect would boost the impact of remdesivir in Covid-19.

The trial aims to recruit 800-1000 patients from 100 medical institutions around the world, including Korea. On May 18, the Seoul National University Hospital received the regulatory nod to join the study with 100 Covid-19 patients.

CytoDyn, a U.S. biotech firm, seeks to win U.S. FDA’s approval for a trial on adding HIV drug candidate leronlimab to remdesivir in Covid-19 treatment. Last year, the FDA granted fast-track status to leronlimab as a treatment for HIV. The company has completed a phase-3 study on the agent.

Leronlimab is an IgG4 monoclonal antibody that blocks CCR5, a cell receptor that causes HIV infection or tumor metastasis, according to CytoDyn. The agent is known to have both antiviral and anti-inflammatory effects.

Leronlimab showed therapeutic effects in 10 critically ill Covid-19 patients when used as emergency Investigational New Drug (eIND), the company said.

CytoDyn said it would prepare a phase-3 trial protocol on leronlimab to submit to the FDA for testing the agent with remdesivir.

The company will divide patients into three groups to compare the effects of leronlimab alone, remdesivir alone, and the combination of the two.

CytoDyn recently inked a deal with Samsung Biologics on the latter’s manufacturing of leronlimab.

My CC summary:
A major concern of Dr. Pourhassan was to clarify the past mistakes of the previous CEO's who now want to go to court. Interim CFO Mulholland determine that they will have no impact on Cytodyn.

Cytodyn is moving forward on a broad front with 10 treatable implications in 2020 and receives confirmation from Dr. Lalezari, that some new cancer patients (round about 10) have been added to the treatment with Leronlimab. In this context, Leronlimab will also be used for compassionate use with FDA approval.

The broad front of 10 implications are to be achieved by a non-dilutive financing from a bank/investment bank via a loan and also to finance the NYSE listing.

Surprisingly, Dr. Pourhassan explained that CytoDyn is in discussion with 6 companies for oncology in discussion with 5 companies for Covid 19 and for HIV in discussion with 2 companies outside the USA.

While current talks are not business, they will certainly lead to future business and agreement on upfront payments and revenue. This brief statement about possible partnerships and agreements in my opinion means a very profitable future for Cytodyn, in one way or another.

The financing planned for the weekend and parallel listing on the NYSE or Nasdaq should be rewarded in the medium term by a higher share price, which in turn will result in much less dilution for the further financing through shares.

The complex Covid-19 documentation paper work for patient recruitment causes a certain time lag and has currently slowed down for a quick FDA approval for Emmergeny Use Application.

According to FDA and Dr. Pourhassan, the Compessionate Use could also delay the final FDA approval for the broad application of Covid-19.

The 1 million vials ordered from Samsung and AGT should be in stock by the end of June and beginning of July. This leads me to conclude and I suspect, that this is one of the reasons, why we are getting slightly delayed FDA approval - no approval without stocked vials!

Another important point is the nomination of a Pharma Manager to drive the business even more actively worldwide. It will be interesting to see from which stable of the big pharmaceutical industry he comes.

All in all everything sounds very positive and next week there could be some good news with the closing of the financing and the timeline for NYSE listing.

Partnerships in various countries with large pharmaceutical companies or pharmaceutical service providers are decorative accessories that should keep the course moving upward.

The most important thing is and remains the results of the study for Covid-19, which can be submitted to the FDA as an interim target for approval even after 50 treated patients as Dr. Pourhassan claimed!

Other Big Pharma companies would wish for such CEO's, at Cytodyn it is even the mandatory to get into the visible radar and attract further investors and partners!

All in my opinion and suggestion why the CC was important!

Scientists find a promising drug to reduce lung inflammation in COVID-19
By Knowridge -May 26, 2020
https://knowridge.com/2020/05/scientists-find-a-promising-drug-to-reduce-lung-inflammation-in-covid-19/

OXFORD Academic medical study includes Leronlimab: How should I manage immunosuppression in a kidney transplant patient with COVID-19?
https://academic.oup.com/ndt/advance-article/doi/10.1093/ndt/gfaa130/5842068
Table:
https://academic.oup.com/view-large/204045890

Leronlimab shows promise as a treatment for COVID-19

https://globaldata.com/leronlimab-shows-promise-as-a-treatment-for-covid-19/

Google trends for Leronlimab in 24 regions:
https://trends.google.de/trends/explore?date=now%201-d&q=leronlimab

Google trends up 650% for CCR5 in 50 regions:
https://trends.google.de/trends/explore?q=%2Fm%2F02kgdfq&date=now%201-d

Google trends for Cytodyn in 18 regions:
https://trends.google.de/trends/explore?date=now%201-d&q=%2Fg%2F1dtt2r0k

RA Capital Covid-19 Analyse
Who we are:
RA Capital funds and builds healthcare and life science companies

https://www.racap.com/covid-19

Therapeutics (Cytodyn in green rectangle and looks like a frontrunner):
There are not so many alternatives anymore, after the hydroxychloroquine (suspended from trials) and remdesevir (no significant results or improvements), especially without side effects (eidd 2801 and all oral medicine) it gets very dark and scaling is not that easy (mesoblast)!



Overall analysis:
https://www.racap.com/media/Covid-19/COVID-19_05222020_F_Thumbnail.png?v=tqQ5pOl-0msFNUBskKsKb3JnZyTa69-O0hXAIx6ImKk

Institution, Funds and Trust buying in CYDY:

2020-05-20 13F Glenmede Trust Co Na 1.00 100,000 0.00 100 0.00
2020-05-13 13F L & S Advisors Inc 1.85 50,500 223.72 135 743.75
2020-05-05 13F Inverness Counsel Llc1.83 15,000 0.00 40 166.67
2020-04-13 13F Livingston Group AM 17,000 45
2020-04-10 13F Diversified Trust Co 1.83 225,500 0.00 601 165.93
2020-04-09 13F Fny Investment Advisers, 1,200 3

https://fintel.io/so/us/cydy

bluefish, leronlimab s mentioned several times with evaluation of positive outcome:

●CCR5を阻害薬によるCOVID-19の過剰免疫の是正
すでに抗HIV薬として承認されているマラビロクが使える？？
→CCR5阻害薬でRANTESの作用をブロックすると、IL-6の減少、CD8細胞数の回復とともにウイルス量が減少するようです。
突然登場のCCR5阻害薬ですが、理屈はこうです。

— influenzer (@influenzer3) May 19, 2020

https://publish.twitter.com/?query=https%3A%2F%2Ftwitter.com%2Finfluenzer3%2Fstatus%2F1262725427690303488&widget=Tweet

Elevated IL-6 and CCL5 (RANTES), decreased CD8 cell count and SARS-CoV-2 viral hemorrhage were observed in 10 patients with severe COVID-19. The figure shows that not only IL-1, IL-6, and IL-8, but also RANTES also increased in relation to severity.

Following administration of the CCR5 inhibitor leronlimab, the CCR5 inhibitor can inhibit its action because it works in conjunction with complete inhibition of the CCR5 receptor in macrophages and T cells and - significant confirmation significant confirmation significant confirmation significant confirmation significant confirmation - confirmation confirmation - confirmation - confirmation - confirmation - confirmation

May 19
ANSWER TO.
@ influenzer3
The figure shows (a) a decrease in IL-6, (b) an increase in CD8 cells, and (c) the resulting normalization of the CD4/8 ratio over time after treatment.

May 19
Consistent with the decrease in IL-6, single cell RNA sequencing showed a decrease in cluster of myeloid cells expressing IL-6 and its related genes. This is a new approach to reduce viral hemorrhage by disrupting the CCL5-CCR5 axis through positive immunosuppression and immunization.

CYDY's patents are related to CCL5 Inhibition, and is included in the footnotes of the since withdrawn patent regarding malavilock. CYDY's pending patents can be found here:

https://patents.google.com/patent/US20190002571A1/en

Japanese influenzer with 7650 followers wrote on twitter:
May 19
Malavilok, already approved as an anti-HIV drug, appears to reduce the amount of virus as well as recovery. The theory behind the sudden emergence of CCR5 inhibitors is this.

May 19
1) Alveolar macrophages and airway cells produce a high level of RANTES by infectious stimuli, and the blocking of CCR5, which is the receptor of RANTES, suppresses the migration of immune cells to the lung, and overactivates them. 2) Could it be possible to block CCR5, which is the receptor of RANTES, to suppress the migration of immune cells to the lung and control the over-activation? This is a hypothesis.
Disruption of the CCL5 / RANTES-CCR5 Pathway Restores Immune Homeostasis and Reduces Plasma Viral ...
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), is now pandemic with nearly three million cases reported to date.
medrxiv.org

-
May 19
---- Elevated IL-6 and CCL5 (RANTES), decreased CD8 cell count and SARS-CoV-2 viral hemorrhage were observed in 10 patients with severe COVID-19. The figure shows that not only IL-1, IL-6, and IL-8, but also RANTES also increased in relation to severity.

Following administration of the CCR5 inhibitor leronlimab, the CCR5 inhibitor can inhibit its action because it works in conjunction with complete inhibition of the CCR5 receptor in macrophages and T cells and - significant confirmation significant confirmation significant confirmation significant confirmation significant confirmation - confirmation confirmation - confirmation - confirmation - confirmation - confirmation

May 19
ANSWER TO.
@ influenzer3
The figure shows (a) a decrease in IL-6, (b) an increase in CD8 cells, and (c) the resulting normalization of the CD4/8 ratio over time after treatment.

May 19
Consistent with the decrease in IL-6, single cell RNA sequencing showed a decrease in cluster of myeloid cells expressing IL-6 and its related genes. This is a new approach to reduce viral hemorrhage by disrupting the CCL5-CCR5 axis through positive immunosuppression and immunization.

・CCR5阻害薬leronlimabの投与後に、マクロファージとT細胞のCCR5レセプターの完全な阻害と、IL-6の減少、CD4/8比の回復、ウイルス血症の有意な減少が確認された。
　RANTESはCCR5に結合して作用するため、CCR5阻害薬でその作用を阻害できます。

— influenzer (@influenzer3) May 19, 2020

Translated with www.DeepL.com/Translator (free version)

China's new X-ray corona warns that "cluster still occurs"
May 25, 2020 6:46

Yapanese NHK reports:
https://translate.google.com/translate?hl=de&sl=ja&tl=en&u=https%3A%2F%2Fwww3.nhk.or.jp%2Fnews%2Fhtml%2F20200525%2Fk10012443351000.html

Agree 100% on your arguments, this should be approved long ago!

But it will be done very soon, i assume!

IMO

Comparison David (Cytodyn) against Goliath (Gilead)
Fox News:
https://www.foxnews.com/science/biotech-covid-19-treatment-trial-combining-experimental-coronavirus-drugs-leronlimab-remdesivir

According to the results of the study, Remdesevir brings almost no improvement in Covid-19 patients!

Remdesevir on NEJM - extract:
Although several therapeutic agents have been evaluated for the treatment of coronavirus disease 2019 (Covid-19), none have yet been shown to be efficacious.
https://www.nejm.org/doi/full/10.1056/NEJMoa2007764

CNN report:
https://edition.cnn.com/2020/05/22/health/remdesivir-covid-19-trial-results-nejm-study/index.html

Zerohedge report:
https://www.zerohedge.com/technology/remdesivir-study-finally-out-drug-only-helped-those-oxygen-finds-mortality-too-high

The results of Leronlimab study will probably bring even more advantages for Cytodyn!